Literature DB >> 25550834

Expression of aryl hydrocarbon receptor in relation to p53 status and clinicopathological parameters in breast cancer.

Zheng-Dong Li1, Kai Wang1, Xin-Wei Yang2, Zhi-Gang Zhuang1, Jian-Jun Wang3, Xiao-Wen Tong3.   

Abstract

The aryl hydrocarbon receptor (AhR) is a ligand activated transcription factor implicated in multiple cellular processes and its expression has been shown to play a critical role in tumorigenesis. However, the role of AhR in tumorigenesis of breast cancer remains unclear. In the current study, we investigated the expression levels of AhR in breast lesions and assessing the correlation between AhR expression and clinicopathological variables using breast cancer tissue microarray. Meanwhile, 10 paired of fresh breast cancer and corresponding non-cancer samples were detected for AhR and p53 expression by Western blot, respectively. Results showed that AhR expression levels in breast cancer tissues were significantly higher than that in the non-cancer tissues. AhR expression was associated with the pathological type and P53 status, but not patients age, tumor grade and TNM, as well as ER, PR, C-erbB2, Ki-67, AR, EGFR status. Moreover, Western blot data suggested a negative correlation between p53 protein and AhR protein expression levels. The results suggest that high levels of AhR were expressed in the majority of breast cancer tissues and closely associated with P53 status and histological types of breast cancer. AHR and its abnormal expression may play an important role in multiple stages of breast cancer progression.

Entities:  

Keywords:  AhR; breast cancer; immunohistochemistry; p53; tissue microarray

Mesh:

Substances:

Year:  2014        PMID: 25550834      PMCID: PMC4270523     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  26 in total

1.  2,3,7,8-tetrachlorodibenzo-p-dioxin counteracts the p53 response to a genotoxicant by upregulating expression of the metastasis marker agr2 in the hepatocarcinoma cell line HepG2.

Authors:  Ariane Ambolet-Camoit; Linh Chi Bui; Stéphane Pierre; Aline Chevallier; Alexandre Marchand; Xavier Coumoul; Michèle Garlatti; Karine Andreau; Robert Barouki; Martine Aggerbeck
Journal:  Toxicol Sci       Date:  2010-03-18       Impact factor: 4.849

Review 2.  Breast cancer: trends, risks, treatments, and effects.

Authors:  London Draper
Journal:  AAOHN J       Date:  2006-10

3.  Comparing of IRS and Her2 as immunohistochemical scoring schemes in gastroenteropancreatic neuroendocrine tumors.

Authors:  Daniel Kaemmerer; Luisa Peter; Amelie Lupp; Stefan Schulz; Jörg Sänger; Richard Paul Baum; Vikas Prasad; Merten Hommann
Journal:  Int J Clin Exp Pathol       Date:  2012-03-25

4.  TCDD mediates inhibition of p53 and activation of ERalpha signaling in MCF-7 cells at moderate hypoxic conditions.

Authors:  Anja Seifert; Helge Taubert; Sabine Hombach-Klonisch; Bernd Fischer; Anne Navarrete Santos
Journal:  Int J Oncol       Date:  2009-08       Impact factor: 5.650

Review 5.  Role of the aryl hydrocarbon receptor in carcinogenesis and potential as a drug target.

Authors:  Stephen Safe; Syng-Ook Lee; Un-Ho Jin
Journal:  Toxicol Sci       Date:  2013-06-14       Impact factor: 4.849

6.  Activation of the aryl hydrocarbon receptor pathway enhances cancer cell invasion by upregulating the MMP expression and is associated with poor prognosis in upper urinary tract urothelial cancer.

Authors:  Masaru Ishida; Shuji Mikami; Eiji Kikuchi; Takeo Kosaka; Akira Miyajima; Ken Nakagawa; Makio Mukai; Yasunori Okada; Mototsugu Oya
Journal:  Carcinogenesis       Date:  2009-09-15       Impact factor: 4.944

7.  Inhibition of constitutive aryl hydrocarbon receptor (AhR) signaling attenuates androgen independent signaling and growth in (C4-2) prostate cancer cells.

Authors:  Cindy Tran; Oliver Richmond; Latayia Aaron; Joann B Powell
Journal:  Biochem Pharmacol       Date:  2012-12-22       Impact factor: 5.858

8.  Relationship between NF-κB, ER, PR, Her2/neu, Ki67, p53 expression in human breast cancer.

Authors:  D O Shapochka; S P Zaletok; M I Gnidyuk
Journal:  Exp Oncol       Date:  2012-12

9.  Association of aryl hydrocarbon receptor and cytochrome P4501B1 expressions in human non-small cell lung cancers.

Authors:  Pinpin Lin; Han Chang; William L Ho; Meng-Hsiang Wu; Jang-Ming Su
Journal:  Lung Cancer       Date:  2003-12       Impact factor: 5.705

10.  Estrogen receptor α and aryl hydrocarbon receptor independent growth inhibitory effects of aminoflavone in breast cancer cells.

Authors:  Ashley M Brinkman; Jiacai Wu; Karen Ersland; Wei Xu
Journal:  BMC Cancer       Date:  2014-05-20       Impact factor: 4.430

View more
  11 in total

1.  Involvement of fine particulate matter exposure with gene expression pathways in breast tumor and adjacent-normal breast tissue.

Authors:  Natalie C DuPré; Yujing J Heng; Benjamin A Raby; Kimberly Glass; Jaime E Hart; Jen-Hwa Chu; Catherine Askew; A Heather Eliassen; Susan E Hankinson; Peter Kraft; Francine Laden; Rulla M Tamimi
Journal:  Environ Res       Date:  2020-04-15       Impact factor: 6.498

Review 2.  Epigenetics of breast cancer: Modifying role of environmental and bioactive food compounds.

Authors:  Donato F Romagnolo; Kevin D Daniels; Jonathan T Grunwald; Stephan A Ramos; Catherine R Propper; Ornella I Selmin
Journal:  Mol Nutr Food Res       Date:  2016-06       Impact factor: 5.914

Review 3.  The Aryl Hydrocarbon Receptor (AhR) in the Aging Process: Another Puzzling Role for This Highly Conserved Transcription Factor.

Authors:  Vanessa Brinkmann; Niloofar Ale-Agha; Judith Haendeler; Natascia Ventura
Journal:  Front Physiol       Date:  2020-01-14       Impact factor: 4.566

4.  Screening of Cellular Stress Responses Induced by Ambient Aerosol Ultrafine Particle Fraction PM0.5 in A549 Cells.

Authors:  Pavlína Šimečková; Soňa Marvanová; Pavel Kulich; Lucie Králiková; Jiří Neča; Jiřina Procházková; Miroslav Machala
Journal:  Int J Mol Sci       Date:  2019-12-13       Impact factor: 5.923

5.  The Prognostic Impact of Intratumoral Aryl Hydrocarbon Receptor in Primary Breast Cancer Depends on the Type of Endocrine Therapy: A Population-Based Cohort Study.

Authors:  Helga Tryggvadottir; Emma Sandén; Sofie Björner; Alessandra Bressan; Maria Ygland Rödström; Somayeh Khazaei; Dean P Edwards; Björn Nodin; Karin Jirström; Karolin Isaksson; Signe Borgquist; Helena Jernström
Journal:  Front Oncol       Date:  2021-05-20       Impact factor: 6.244

6.  A Comprehensive Pan-Cancer Analysis of 33 Human Cancers Reveals the Immunotherapeutic Value of Aryl Hydrocarbon Receptor.

Authors:  Zhuomao Mo; Pan Li; Zhirui Cao; Shijun Zhang
Journal:  Front Immunol       Date:  2021-07-05       Impact factor: 7.561

7.  An Aryl Hydrocarbon Receptor-Mediated Amplification Loop That Enforces Cell Migration in ER-/PR-/Her2- Human Breast Cancer Cells.

Authors:  Olga Novikov; Zhongyan Wang; Elizabeth A Stanford; Ashley J Parks; Alejandra Ramirez-Cardenas; Esther Landesman; Israa Laklouk; Carmen Sarita-Reyes; Daniel Gusenleitner; Amy Li; Stefano Monti; Sara Manteiga; Kyongbum Lee; David H Sherr
Journal:  Mol Pharmacol       Date:  2016-08-29       Impact factor: 4.436

Review 8.  The Aryl Hydrocarbon Receptor and Tumor Immunity.

Authors:  Ping Xue; Jinrong Fu; Yufeng Zhou
Journal:  Front Immunol       Date:  2018-02-13       Impact factor: 7.561

9.  A novel naphthalimide that selectively targets breast cancer via the arylhydrocarbon receptor pathway.

Authors:  J Gilbert; G N De Iuliis; A McCluskey; J A Sakoff
Journal:  Sci Rep       Date:  2020-08-19       Impact factor: 4.379

10.  Epigenetic Activation of BRCA1 by Genistein In Vivo and Triple Negative Breast Cancer Cells Linked to Antagonism toward Aryl Hydrocarbon Receptor.

Authors:  Micah G Donovan; Ornella I Selmin; Thomas C Doetschman; Donato F Romagnolo
Journal:  Nutrients       Date:  2019-10-23       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.